Enliven Therapeutics Q2 EPS $(0.49) Misses $(0.40) Estimate
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.40) by 22.5 percent. This is unchanged from the same period last year.
Enliven lost more money per share than experts thought it would—49 cents instead of 40 cents. When a company loses more than expected, it shows things might be tougher than people hoped, so it's worth watching to see if the company can turn things around.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.